 |
 |
|
|
 Sativex® can currently be prescribed under section 29 (Unapproved Medicine) of the Medicines Act 1981. The following document is available on the Medsafe Website and is intended for use only by medical professionals resident in New Zealand: Sativex® (standardised cannabis pharmaceutical): requirements for Physician Application-approval GW Pharma has submitted an application to Medsafe for consideration under section 23 (Provisional Consent). This review is on going and an outcome is expected during 2008. For enquiries regarding Sativex® please contact GW Pharma using the details below: |
|
| © GW Pharmaceuticals 2009 |
 |
- Home
- Corporate Information
Management Team-
- Management Team
- Board of Directors
- Committees of the Board
- Senior Management Team
- Job Vacancies
- Links
- Investor Relations
- Introduction
- Financial Performance
-
- Key Financial Data
- Reports & Accounts
- Share Price
- Share Charts
- Securities in Issue
- Press & News
-
- Press Releases
- RNS Announcements
- Shareholder Info
-
- FAQs
- Financial Calendar
- Shareholder Services
- Contacts
- Info Request
- News Alert
-
- Alert Service
- Presentations
- AIM Rule 26
- Research & Development
- Introduction
- Product Pipeline
- Intellectual Property Rights
- Cannabinoid Medications
-
- Cannabinoids
- Mechanism of Action
- Intoxication
- Sativex®
- Cultivation
- Clinical Trials Review
- Clinical Publications
- Cannabinoid ResearchInstitute (CRI)
- Advanced Dispensing System (ADS)
-
- Introduction to ADS
- Drug Addiction
- Other Applications of ADS
- FAQs
- News & Media
- Press Releases
- Notes for Editors
- Sativex®
- United States
- Contact Us
| Search | |
 |
 |
| Site Map |
| Privacy Statement |
| Disclosure & Disclaimer |